RSABE [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2014-03-24 18:25 (4480 d 08:56 ago) – Posting: # 12696
Views: 12,975

Hi Lucas,

see FDA’s progesterone guidance containing SAS-code. If you don’t have SAS, see this post for Phoenix/WinNonlin. Some background about FDA’s/EMA’s approaches.
The problems with FDA’s mixed-effects model start if you are not allowed to scale (CVWR<30%) and have a partial replicate design. Sometimes software (with the FA0(2) covariance structure given in the guidance) fails to converge. Then you have invested in a lot of money and don’t get a result…
I would avoid the partial replicate TRR|RTR|RRT and opt for one of the fully replicated designs (TRT|RTR or TRTR|RTRT) instead.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,570 registered users;
331 visitors (0 registered, 331 guests [including 30 identified bots]).
Forum time: 04:22 CEST (Europe/Vienna)

It requires a very unusual mind
to undertake the analysis of the obvious.    Alfred North Whitehead

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5